Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 15294 | 14.995 |
09:34 ET | 1837 | 14.98 |
09:36 ET | 100 | 14.935 |
09:38 ET | 300 | 14.99 |
09:39 ET | 1207 | 14.9849 |
09:41 ET | 1400 | 14.95 |
09:43 ET | 4727 | 14.92 |
09:45 ET | 7399 | 14.89 |
09:48 ET | 1713 | 14.89 |
09:50 ET | 922 | 14.87 |
09:52 ET | 2335 | 14.88 |
09:54 ET | 1530 | 14.92 |
09:56 ET | 2336 | 14.93 |
09:57 ET | 1503 | 14.94 |
09:59 ET | 5989 | 14.9 |
10:01 ET | 2728 | 14.93 |
10:03 ET | 1530 | 14.915 |
10:06 ET | 1116 | 14.87 |
10:08 ET | 1640 | 14.88 |
10:10 ET | 1323 | 14.87 |
10:12 ET | 6131 | 14.878 |
10:14 ET | 4855 | 14.85 |
10:15 ET | 5888 | 14.8 |
10:17 ET | 1053 | 14.8087 |
10:19 ET | 1393 | 14.79 |
10:21 ET | 13284 | 14.8091 |
10:24 ET | 7460 | 14.79 |
10:26 ET | 2399 | 14.75 |
10:28 ET | 700 | 14.75 |
10:30 ET | 2863 | 14.74 |
10:32 ET | 3198 | 14.775 |
10:33 ET | 6428 | 14.8 |
10:35 ET | 4995 | 14.82 |
10:37 ET | 5408 | 14.86 |
10:39 ET | 2387 | 14.855 |
10:42 ET | 3469 | 14.85 |
10:44 ET | 3315 | 14.81 |
10:46 ET | 1954 | 14.8075 |
10:48 ET | 6891 | 14.8 |
10:50 ET | 5117 | 14.835 |
10:51 ET | 825 | 14.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.5B | 81.7x | --- |
Azenta Inc | 2.3B | -16.8x | --- |
Guardant Health Inc | 2.8B | -5.4x | --- |
PTC Therapeutics Inc | 2.8B | -5.6x | --- |
Novavax Inc | 2.4B | -5.3x | --- |
Catalyst Pharmaceuticals Inc | 2.4B | 37.1x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $890.5M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $0.18 |
Book Value | $2.62 |
P/E Ratio | 81.7x |
Price/Sales (TTM) | 2.8 |
Price/Cash Flow (TTM) | 59.7x |
Operating Margin | 2.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.